05:33 PM EST, 11/21/2025 (MT Newswires) -- Joseph P Lyssikatos, Chief Scientific Officer, on November 19, 2025, sold 12,500 shares in Enliven Therapeutics ( ELVN ) for $279,155. Following the Form 4 filing with the SEC, Lyssikatos has control over a total of 902,688 common shares of the company, with 902,688 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1672619/000196715025000007/xslF345X05/form4-11212025_101158.xml